Ticker: MLTX (MoonLake Immunotherapeutics)
Sector: Biotechnology
Original Analysis Date: September 30, 2025
Profit Update Published: October 8, 2025
Trade Type: LEAPS Call Option (Approx. 500 DTE)
Entry Price: $2.63
Exit Price (GTC Trigger): $4.70
Holding Period: 8 days
Profit: +78.7% or +$207 per contract
🧭 Overview
When we first released our MLTX stock options analysis on September 30, 2025, our thesis was built on the 12-Pillar Alpha+ Hedge Fund Stock Selection Framework. At that time, we emphasized the stock’s biotech volatility compression, improving momentum, and potential for implied volatility (IV) expansion leading into Q4 catalysts.
We specifically selected a LEAPS Call with roughly 500 days to expiration to capitalize on vega sensitivity and time cushion — allowing us to exploit IV rise and directional delta gain simultaneously.
Here’s the original stock options analysis article: 📈 MLTX Stock Options Analysis — LEAPS Vega/Delta Play into the Next Catalyst
Our plan was simple yet structured:
- Enter near $2.63 per contract
- Set a GTC Sell-to-Close at +80% profit
- Hold a maximum of 2 months unless target hit sooner
Today(October 8, 2025), that plan worked perfectly. The position automatically closed at $4.70, delivering a near 80% profit without requiring daily monitoring or emotional decisions.
Had you listened to our previous article and entered a position when we published on September 30 — while also setting the same GTC target — you would have automatically profited around $207 per contract, or $2,070 for every 10 contracts traded.
📈 Profit Breakdown
Let’s put the numbers into perspective — this wasn’t just a small win.
- Initial Cost per Contract: $2.63 × 100 = $263
- Exit Value per Contract: $4.70 × 100 = $470
- Net Profit per Contract: $470 − $263 = $207
- Percentage Gain: ((4.70 − 2.63) ÷ 2.63) × 100 = +78.7%
Now, imagine scaling that simple setup:
💰 10 contracts would have turned a $2,630 investment into $4,700, netting a clean $2,070 profit in just 8 days.
💰 50 contracts? That same move would have generated over $10,000 in pure profit.
💰 100 contracts would have produced a stunning $20,700 gain — all from a single disciplined, automated trade.
This wasn’t luck — it was a textbook execution of our 12-Pillar Alpha+ Options Framework, combining:
- Strong technical setup,
- Timely volatility forecasting, and
- Emotion-free automated profit-taking via a GTC sell order.
It’s proof that with a structured plan, even a mid-sized position can deliver five-figure results in a matter of days — without chasing or overtrading.
🧩 Then vs. Now — Chart Review
[OLD Chart – September 30, 2025]
When we issued the initial buy signal, MLTX had just begun recovering from a heavy selloff. RSI hovered around 45, MACD histogram flipped positive, and price was consolidating just below $9.25 resistance while hugging the VWAP midline — signaling that accumulation was quietly underway.
[NEW Charts – October 8, 2025]
Fast forward to today: MLTX rallied sharply, triggering a chain of short-term bullish momentum signals. The stock hit our predefined GTC level and later retraced to consolidate near the $9.07–$9.21 support range.
The RSI (5-minute) now stabilizes around 40–45, indicating a cooling phase after the surge, while the 30-minute and daily MACD both show signs of base rebuilding.
🧠 Multi-Timeframe Technical Recap
- 5-Minute View: MLTX maintains support above $9.04, with RSI recovering from intraday oversold conditions. Short-term traders are likely taking profit, which is healthy post-spike behavior.
- 30-Minute View: RSI at 55–56 and steady MACD crossover confirm neutral-to-bullish sentiment. Volume remains moderate, suggesting consolidation rather than capitulation.
- 1-Day View: RSI near 34 reflects a post-breakout reset, while MACD shows deep trough recovery — early signs of momentum rebuilding for the next potential swing.
This is consistent with Hedge Fund Pillar #7 (Technical Strength) — maintaining structure above 200-day VWAP and forming higher lows after profit-taking events.
💡 Lessons & Takeaways
This MLTX trade is a perfect showcase of how planning beats prediction.
By sticking to the plan — enter, automate, and walk away — we turned volatility into opportunity.
- Discipline: The GTC order removed emotion from the equation.
- Timing: Early entry before IV expansion captured the sweet spot.
- Structure: Using LEAPS allowed vega and delta to compound favorably.
In less than two weeks, this position yielded nearly double the initial investment — all while staying within our 2% risk allocation per trade rule.
🔮 What’s Next for MLTX
Although our initial MLTX LEAPS position has already closed with an 80% profit, this biotech name still deserves close attention — and possibly, a second entry opportunity for those who missed the first wave.
After the steep post-rally drop, MLTX now trades nearly 80% below its former highs, reflecting a sharp market overreaction rather than a fundamental collapse. The daily chart shows that the stock has stabilized around the $9.00–$9.10 support area, where volume accumulation is quietly increasing. RSI remains low near 35, and the MACD is beginning to flatten — early signs of potential base formation.
This correction, though aggressive, presents an ideal environment for contrarian LEAPS positioning. The recent analyst updates further strengthen the bullish case:
- Oppenheimer set a fresh target of $25,
- Needham and Guggenheim reiterated targets around $20,
- while earlier high-end estimates from H.C. Wainwright ($100) and Goldman Sachs ($62) show that Wall Street still values MLTX’s pipeline well above current levels.
Taken together, these projections point to substantial upside potential if sentiment normalizes and the company executes on its upcoming catalysts.
🎯 Updated LEAPS Strategy (Re-Entry Opportunity)
Based on the latest January 2027 options chain (≈464 DTE), the optimal strike for re-entry is currently the $20 Call, which balances delta and vega sensitivity effectively.
- Strike: $20 Call
- Expiration: January 15, 2027 (464 DTE)
- Delta: 0.50 — providing roughly 2x leverage on stock movement
- Vega: 0.041 — strong sensitivity to volatility expansion
- Open Interest: 383 — healthy liquidity for longer-dated contracts
This setup aligns perfectly with our two-month hold window strategy, giving ample time to benefit from volatility recovery while managing downside risk.
Our plan for this new potential setup would be:
- Batch 1 Entry: Near current price ($9–$9.10 stock level).
- Batch 2 Entry: If the option price drops 40–50% from the first entry cost.
- Batch 3 Entry: Another 40–50% drawdown from Batch 2’s option cost.
This scaling method allows averaging down efficiently while maintaining risk control and exposure for a medium-term rebound.
💡 Big Picture
Had you listened to our previous article and entered the first MLTX position back in September with a GTC +80% sell target, your trade would have automatically closed at $4.70 per contract, locking in $207 profit per contract — or $2,070 on a 10-contract position.
Yet, despite that successful run, MLTX’s current correction has effectively reset the chart, opening a new opportunity window for traders willing to re-enter before the next biotech rotation.
With the stock sitting at multi-month lows, RSI beginning to rise, and analysts reaffirming high conviction targets ($20–$100 range), this remains one of the most asymmetric setups on the biotech watchlist heading into Q4 2025.
⚙️ Suggested Execution
Reassess technicals near mid-November for potential position rollover.
Monitor RSI for a climb above 40 to confirm early momentum.
Enter the Jan 2027 $20C LEAPS in 3 batches per standard Alpha+ entry plan.
Set GTC Sell-to-Close orders around +80% profit levels to automate exits.
⚠️ Legal Disclaimer
This article is for informational and educational purposes only and does not constitute investment advice, recommendations, or solicitation to buy or sell securities or options.
Options trading carries significant risk and may not be suitable for all investors. Past performance does not guarantee future results.
All trades discussed are for illustrative purposes only. VIXTradingHub and its contributors do not hold any current position in MLTX at the time of publication. Always conduct your own research and consult a licensed financial advisor before trading.
